Lenvatinib Mesylate Patent Expiration
Lenvatinib Mesylate is Used for treating thyroid carcinoma, including differentiated thyroid cancer, by administering Lenvima as a suspension. It was first introduced by Eisai Inc
Lenvatinib Mesylate Patents
Given below is the list of patents protecting Lenvatinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lenvima |
US11090386 (Pediatric) | Method for suppressing bitterness of quinoline derivative | Aug 23, 2036 | Eisai Inc |
| Lenvima | US12083112 | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer | Mar 03, 2036 | Eisai Inc |
| Lenvima |
US10259791 (Pediatric) | High-purity quinoline derivative and method for manufacturing same | Feb 26, 2036 | Eisai Inc |
| Lenvima |
US10407393 (Pediatric) | High-purity quinoline derivative and method for manufacturing same | Feb 26, 2036 | Eisai Inc |
| Lenvima |
US11186547 (Pediatric) | High-purity quinoline derivative and method for manufacturing same | Feb 26, 2036 | Eisai Inc |
| Lenvima | US11090386 | Method for suppressing bitterness of quinoline derivative | Feb 23, 2036 | Eisai Inc |
| Lenvima | US10259791 | High-purity quinoline derivative and method for manufacturing same | Aug 26, 2035 | Eisai Inc |
| Lenvima | US10407393 | High-purity quinoline derivative and method for manufacturing same | Aug 26, 2035 | Eisai Inc |
| Lenvima | US11186547 | High-purity quinoline derivative and method for manufacturing same | Aug 26, 2035 | Eisai Inc |
| Lenvima |
US9006256 (Pediatric) | Antitumor agent for thyroid cancer | Jan 27, 2028 | Eisai Inc |
| Lenvima | US9006256 | Antitumor agent for thyroid cancer | Jul 27, 2027 | Eisai Inc |
| Lenvima |
US7612208 (Pediatric) | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | Mar 19, 2027 | Eisai Inc |
| Lenvima | US7612208 | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | Sep 19, 2026 | Eisai Inc |
| Lenvima |
US7253286 (Pediatric) | Nitrogen-containing aromatic derivatives | Apr 24, 2026 | Eisai Inc |
| Lenvima | US7253286 | Nitrogen-containing aromatic derivatives | Oct 24, 2025 | Eisai Inc |
Lenvatinib Mesylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List